NAD(P) H酸化酵素と多剤耐性タンパク質の遺伝的多形態化は,ドクソルビシン誘発の心臓毒性に関連しています
Leszek Wojnowski1, Bettina Kulle, Markus Schirmer
1Department of Pharmacology, University Mainz, D-55101 Mainz, Germany. Wojnowski@uni-mainz.de
Circulation
|December 7, 2005
まとめ
薬物の輸送と代謝における遺伝的変異は,アントラサイクリン誘発性心臓毒性 (ACT) リスクに影響します. これらの薬剤ゲノミクス予測因子を特定することで,がん治療をパーソナライズし,心臓の損傷を軽減するのに役立ちます.
科学分野:
- ファルマコゲノミクスとは
- 心臓病学 心臓病学
- 腫瘍学 腫瘍学
背景:
- アントラサイクリン化学療法により,心臓毒性 (ACT) が起こり,心律不全や心不全を引き起こす可能性があります.
- 現在,ACTの薬理遺伝学的な予測要因は確立されていません.
研究 の 目的:
- アントラサイクリン誘発性心臓毒性 (ACT) の予測因子としての遺伝的変異を調査する.
主な方法:
- ゲノタイプ化された1697人のノンホジキンリンパ腫患者は,82の関連する遺伝子で単核性多型性 (SNP) を検出しました.
- ACTの急性および慢性発症を記録するために,患者さんを平均3年以上追跡した.
- 分析されたSNPとACT発生の関連性,NAD,P) H酸化酵素とドクソルビシントランスポーター遺伝子を含む.
主要な成果:
- ACTとNAD(P) H酸化酵素サブユニット (NCF4,CYBA,RAC2) とドクソルビシン流出トランスポーター (MRP1,MRP2) のポリモルフィズムとの間に有意な関連性を特定しました.
- NCF4 (rs1883112) とCYBA (rs4673) のような特定の変異は,それぞれ慢性および急性ACTに関連していた.
- NAD(P) H酸化酵素活性が欠如したマウスはドクソルビシンに対する耐性を示し,この経路の役割をサポートしました.
結論:
- ドクソルビシン輸送とフリーラジカル代謝に関与する遺伝子の遺伝的変異は,ACTリスクと関連しています.
- これらの発見は,薬剤ゲノムプロファイリングが,アントラサイクリンを投与している患者のACTの予測と管理に役立つことを示唆しています.
関連する概念動画
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
350
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
350
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
190
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
190
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Drug Toxicity: Risk factors
250
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
250
Drug toxicity: Idiosyncratic Reactions
232
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
232


